NCT05756777 - A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Gilteritinib

Dose level (-1) 80mg, (1) 120mg, (2) 120mg

DRUG

Ivosidenib

Dose level (-1) 250mg, (1) 250mg, (2) 500mg

DRUG

Enasidenib

Dose level (-1) 50mg, (1) 50mg, (2) 100mg

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau, Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack, Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth, Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors

collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER